FHND5071: a selective RET inhibitor with unique pharmacokinetic profile

被引：1
|
作者：
Zhu, Yongqiang
Wang, Jia
Shang, Minghong
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-LB330
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FHND5071
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series
    Contrera, Kevin J.
    Gule-Monroe, Maria K.
    Hu, Mimi I.
    Cabanillas, Maria E.
    Busaidy, Naifa L.
    Dadu, Ramona
    Waguespack, Steven G.
    Wang, Jennifer R.
    Maniakas, Anastasios
    Lai, Stephen Y.
    Diersing, Julia
    Kwon, Michael
    Grubbs, Elizabeth G.
    Subbiah, Vivek
    Williams, Michelle D.
    Zafereo, Mark E.
    THYROID, 2023, 33 (01) : 129 - 132
  • [22] AR882, a Potent and Selective URAT1 Inhibitor with a Favorable Pharmacological, Pharmacokinetic and Toxicity Profile
    Yan, Rongzi
    Zhu, Nanqun
    Shen, Zancong
    Yan, Shunqi
    Yeh, Litain
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [23] BLU-667 is a potent and highly selective RET inhibitor being developed for RET-driven cancers
    Rahal, Rami
    Maynard, Michelle
    Hu, Wei
    Brubaker, Jason
    Cao, Qiongfang
    Kim, Joseph L.
    Sheets, Michael P.
    Wilson, Douglas P.
    Wilson, Kevin J.
    DiPietro, Lucian
    Fleming, Paul
    LaBranche, Timothy P.
    Wolf, Beni
    Guzi, Timothy
    Lengauer, Christoph
    Evans, Erica K.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [24] Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
    Karin G. Schrenk
    Wolfram Weschenfelder
    Christian Spiegel
    Abbas Agaimy
    Robert Stöhr
    Arndt Hartmann
    Nikolaus Gaßler
    Robert Drescher
    Martin Freesmeyer
    Amer Malouhi
    Florian Bürckenmeyer
    René Aschenbach
    Ulf Teichgräber
    Christine Kögler
    Matthias Vogt
    Gunther O. Hofmann
    Andreas Hochhaus
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5493 - 5496
  • [25] Novel therapeutic agents for RET-driven cancers, which is highly potent and selective inhibitor to RET kinase
    Li, Hua
    Jo, SeoHyun
    Do, Woomi
    Kim, Hyunkyung
    Kim, Hwan
    Seo, Kyung-ah
    Oh, Ji-hoon
    Choi, Jieun
    Ahn, Jaeyoung
    Son, Jung Beom
    Kim, Nam Doo
    CANCER RESEARCH, 2019, 79 (13)
  • [26] Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
    Schrenk, Karin G.
    Weschenfelder, Wolfram
    Spiegel, Christian
    Agaimy, Abbas
    Stoehr, Robert
    Hartmann, Arndt
    Gassler, Nikolaus
    Drescher, Robert
    Freesmeyer, Martin
    Malouhi, Amer
    Buerckenmeyer, Florian
    Aschenbach, Rene
    Teichgraeber, Ulf
    Koegler, Christine
    Vogt, Matthias
    Hofmann, Gunther O.
    Hochhaus, Andreas
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (09) : 5493 - 5496
  • [27] Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir
    Srinivasan Ramanathan
    Anita A. Mathias
    Polina German
    Brian P. Kearney
    Clinical Pharmacokinetics, 2011, 50 : 229 - 244
  • [28] Clinical Pharmacokinetic and pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir
    Ramanathan, Srinivasan
    Mathias, Anita A.
    German, Polina
    Kearney, Brian P.
    CLINICAL PHARMACOKINETICS, 2011, 50 (04) : 229 - 244
  • [29] Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement
    Piotrowska, Z.
    Isozaki, H.
    Lennerz, J.
    Digumarthy, S.
    Gainor, J.
    Marcoux, N.
    Banwait, M.
    Dias-Santagata, D.
    Lafrate, A. J.
    Mino-Kenudson, M.
    Nagy, R.
    Lanman, R.
    Evans, E.
    Clifford, C.
    Wolf, B.
    Hata, A.
    Sequist, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S451 - S451
  • [30] A potent and selective RET inhibitor with efficacy in RET-driven mouse models of medullary thyroid carcinoma and lung adenocarcinoma
    Watson, Mandy
    Small, Helen
    Acton, Ben
    Begum, Habiba
    Hitchin, Samantha
    Jordan, Allan
    Kelly, Paul
    Newton, Rebecca
    Waddell, Ian
    Paris, Gina
    Ogilvie, Donald
    CANCER RESEARCH, 2017, 77
12345